Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025

Core Viewpoint - Addex Therapeutics will report its Q3 2025 financial results on December 4, 2025, and provide a business update along with a review of its product pipeline during a teleconference and webcast [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3] - Addex's partner, Indivior, is developing a GABAB PAM drug candidate for substance use disorders, having completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough [3] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for schizophrenia, psychosis, mood-related disorders, and mood disorders [3] - Additionally, Addex has invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [3] Financial Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [4]